Advertisement

Prostate Cancer Medications

Here's a list of the approved drugs to treat prostate cancer. Click on any of the medications for more info on indications, dosing and side effects.


Quick Filter

*generic version available

E experimental

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Casodex
GENERIC NAME bicalutamide
DRUG INDICATION

Casodex is an androgen receptor inhibitor approved for metastatic prostate cancer.

DRUG Erleada
GENERIC NAME apalutamide
DRUG INDICATION

Erleada is an androgen receptor inhibitor approved for nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration resistant).

DRUG Eulexin
GENERIC NAME flutamide
DRUG INDICATION

Eulexin is an anti-androgen drug approved for locally confined metastatic prostate cancer.

DRUG Firmagon
GENERIC NAME degarelix
DRUG INDICATION

Firmagon is a GnRH receptor blocker approved for advanced prostate cancer.

DRUG Lupron
GENERIC NAME leuprolide
DRUG INDICATION

Lupron is a GnRH agonist approved for palliative treatment of advanced prostate cancer. It is also used to treat breast and ovarian cancer, though it is not FDA-approved for these indications.

DRUG Nilandron
GENERIC NAME nilutamide
DRUG INDICATION

Nilandron is an anti-androgen drug used to treat men with metastatic prostate cancer after surgical castration, or removal of the testicles.

DRUG Nubeqa
GENERIC NAME darolutamide
DRUG INDICATION

Nubeqa is an androgen receptor inhibitor approved for the treatment of nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant).

DRUG Trelstar
GENERIC NAME triptorelin
DRUG INDICATION

Trelstar is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

DRUG Vantas
GENERIC NAME histrelin
DRUG INDICATION

Vantas is a GnRH agonist approved for palliative treatment of advanced prostate cancer.

DRUG Xtandi
GENERIC NAME enzalutamide
DRUG INDICATION

Xtandi is an androgen receptor inhibitor approved for metastatic or nonmetastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant).

DRUG Zoladex
GENERIC NAME goserelin
DRUG INDICATION

Zoladex is a GnRH agonist approved for palliative treatment of advanced prostate cancer and, treatment of localized prostate cancer in combination with Eulexin (flutamide) and palliative treatment of breast cancer in premenopausal women. It is also used to treat ovarian cancer, though it is not FDA-approved for this indication.

DRUG Zytiga
GENERIC NAME abiraterone
DRUG INDICATION

Zytiga is a CYP17 inhibitor approved for metastatic prostate cancer that progresses despite low testosterone levels (known as castration-resistant) and for high-risk castration-sensitive prostate cancer.

DRUG Provenge
GENERIC NAME sipuleucel-T
DRUG INDICATION

Provenge is a personalized cancer vaccine approved for metastatic prostate cancer that does not respond to hormone therapy (known as castration-resistant).

DRUG Rozlytrek
GENERIC NAME entrectinib
DRUG INDICATION

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

DRUG Vitrakvi
GENERIC NAME larotrectinib
DRUG INDICATION

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.


Advertisement